# Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD

Study · id `cardio:ct-nct06449833` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06449833](<https://clinicaltrials.gov/study/NCT06449833>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06449833

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06449833. Randomized; double masking; primary purpose treatment. Start 2024-06 (anticipated); primary completion 2026-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06449833, source copy `cardio:ctgov-nct06449833-2024-06-10`, retrieved 2026-10-26)
- Planned start: 2024-06 (anticipated) (ClinicalTrials.gov record NCT06449833, source copy `cardio:ctgov-nct06449833-2024-06-10`, retrieved 2026-10-26)
- Primary completion: 2026-11 (anticipated) (ClinicalTrials.gov record NCT06449833, source copy `cardio:ctgov-nct06449833-2024-06-10`, retrieved 2026-10-26)
- Completion: 2026-11 (anticipated) (ClinicalTrials.gov record NCT06449833, source copy `cardio:ctgov-nct06449833-2024-06-10`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06449833, source copy `cardio:ctgov-nct06449833-2024-06-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06449833-2024-06-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
- Acronym: HHTN
- Condition: Type2 Diabetes Mellitus
- Condition: Nonalcoholic Fatty Liver Disease
- Intervention (Drug): Henagliflozein and Metformin
- Intervention (Drug): Linagliptin and Metformin
- Lead sponsor: Zhujiang Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Zhujiang Hospital (`cardio:org-zhujiang-hospital`)

## Provenance

Content hash: e49e365028bc595529f82f8ec8ddff2fa24d2f322c6d7128ab9a5c8ebe5f3aae
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
